HEALIOS K.K.
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
4593 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 千代田区有楽町一丁目７番１号
- Website:
- https://www.healios.co.jp/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Healios K.K. is a biotechnology company specializing in the research, development, and manufacturing of cell therapy and regenerative medicine products. A pioneer in the field, the company develops treatments for diseases with high unmet medical needs by leveraging induced pluripotent stem (iPS) cell technology and somatic stem cells. Its core R&D focuses on creating therapies from iPS cell-derived products, including retinal pigment epithelium (RPE) cells and Natural Killer (NK) cells for cancer immunotherapy. The company's pipeline also features somatic stem cell products like HLCM051 (MultiStem) for treating conditions such as acute respiratory distress syndrome (ARDS). Healios utilizes proprietary gene editing technology to develop next-generation universal donor cells, aiming to overcome immune rejection and broaden the application of cellular medicine.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HEALIOS K.K. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-13 05:35 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-08-13 05:34 |
Interim Report
半期報告書－第15期(2025/01/01－2025/12/31)
|
Japanese | 436.9 KB | |
| 2025-05-13 08:33 |
Regulatory News Service
臨時報告書
|
Japanese | 19.7 KB | |
| 2025-03-27 07:22 |
Regulatory News Service
臨時報告書
|
Japanese | 25.4 KB | |
| 2025-03-27 07:21 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2025-03-27 07:20 |
Regulatory News Service
内部統制報告書－第14期(2024/01/01－2024/12/31)
|
Japanese | 21.7 KB | |
| 2025-03-27 07:19 |
Annual Report
有価証券報告書－第14期(2024/01/01－2024/12/31)
|
Japanese | 2.0 MB | |
| 2025-02-14 05:13 |
Regulatory News Service
訂正臨時報告書
|
Japanese | 37.5 KB | |
| 2025-02-14 04:07 |
Regulatory News Service
臨時報告書
|
Japanese | 21.3 KB | |
| 2025-01-27 07:31 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 224.3 KB | |
| 2025-01-22 07:33 |
Regulatory News Service
臨時報告書
|
Japanese | 53.3 KB | |
| 2024-11-13 07:34 |
Regulatory News Service
臨時報告書
|
Japanese | 20.0 KB | |
| 2024-08-13 08:04 |
Regulatory News Service
臨時報告書
|
Japanese | 19.9 KB | |
| 2024-08-13 08:04 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-08-13 08:03 |
Interim Report
半期報告書－第14期(2024/01/01－2024/12/31)
|
Japanese | 402.0 KB |
Automate Your Workflow. Get a real-time feed of all HEALIOS K.K. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for HEALIOS K.K. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
